A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
Conditions
Interventions
- DRUG: Exenatide Circular RNA-Lipid Nanoparticle Injection( CR059))
Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Collaborators